FindTrial
Sign In

The inhibitory effect of human beta-defensin-3 (hBD-3) on different Candida spp. isolated from patients with Candidiasis

The inhibitory effect of human beta-defensin-3 (hBD-3) on different Candida spp. isolated from patients with Candidiasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20181204001
Enrollment
8
Registered
2018-12-04
Start date
2018-11-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To investigate the inhibitory effect and/or additive&#44

Interventions

Human beta&#45
defensins&#45
3 (hBD&#45
3) is a type of human antimicrobial peptides (AMPs) and thereby cause pore formation leading to disruption of the microbial cell membrane. hBD&#45
3 shows the highest positive charge in this group and eliminates a broad range of pathogens such as gram&#45
positive and gram&#45
negative bacteria&#44
viruses and fungi including Candida spp.
Experimental Other
human beta&#45
defensin 3

Sponsors

Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0 Years to 0 Years

Inclusion criteria

Inclusion criteria: Candida glabrata clinical isolated strain from patient with candidiasis

Exclusion criteria

Exclusion criteria: patient who not candida infected

Design outcomes

Primary

MeasureTime frame
Antifungal susceptibility 48 hours after incubate yeast with antifungal drug MIC Score using CLSI method—

Secondary

MeasureTime frame
hBD-3 gene and protein expression on epithelial cells after C. glabrata stimulation 24, 48 and 72 hour after incubate ELISA—

Countries

Thailand

Contacts

Public ContactDirekrit Chiewchengchol

ีunaffiliated

Chiewchengchol02-2564470

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026